他31岁，已经开过5家公司

维韦克•拉玛斯旺米（Vivek Ramaswamy）又一次创立了新公司。这位由对冲基金投资人转型的生物技术创业家现年31岁，他在药物研究与开发上的做法让他跻身《财富》（Fortune）2017年改变医疗行业的领袖榜单，也让他遭遇了许多质疑。他建立了自己的第五家生物科技公司Urovant，重点研究膀胱过度活动症等泌尿系统疾病。

拉玛斯旺米在声明中说：“我们很高兴在公司的家族里又加入了一位新成员。膀胱过度活动症等泌尿系统疾病影响了无数人，目前的治疗方式无法满足很多病人的要求。我们的目标就是尽快给病人提供更好的选择。”

Urovant与制药公司默沙克（Merck）达成了授权协议，有权获得后者治疗膀胱过度活动症的最新临床药品Vibegron。根据泌尿学护理基金会（Urology Care Foundation）的数据，这种病症以各种形式折磨着大约3,300万美国人。

拉玛斯旺米是Roivant Sciences的创始人和首席执行官，这是他一系列生命科学公司（都以Vant作为名字结尾）的母公司。在生物制药圈以外，他最为人所知的事情是让数家生物技术公司上市，其中重点治疗阿兹海默症和神经系统疾病的公司Axovant募资达到3.15亿美元，专注女性健康的公司Myovant也募得了2.18亿美元。（怀疑者认为，这种模式不可持续，公司在没有什么证据表明自己能取得最终成功的情况下，创造了巨大的估值。）

Roivant旗下还有另外两家公司，分别专注于皮肤问题和罕见疾病，这两家公司目前还属于私有。今年4月，前Medivation首席执行官大卫•洪【该公司由于前列腺癌的治疗药物Xtandi，去年被辉瑞制药（Pfizer）收购】成为了Axovant的新任首席执行官。

在上个月接受《财富》采访时，拉玛斯旺米表示，他的做法主要包括获取其他公司（尤其是大型药品公司）没有资源将其用于临床试验，或因为不符合自身药品组合战略而不感兴趣，或认定为收益低/风险高的具有潜力的试验性药物。

接下来他要做什么呢？根据过去三年的情况来推断，他应该会达成更多许可协议，获取更多试验性药物，高调地招聘更多员工。（财富中文网）

译者：严匡正

Vivek Ramaswamy has done it again. The 31-year-old hedge-funder-turned-biotech wunderkind—whose approach to drug research and development has earned him both plenty of skeptics and a place on Fortune's 2017 list of leaders who are changing health care—is launching his fifth biotech company, Urovant, which will focus on urological disorders like overactive bladder.

"We are delighted to welcome another ‘Vant’ to our growing family of companies," said Ramaswamy in a statement. "Urologic conditions such as overactive bladder adversely impact millions of individuals, and the current treatment options are unsatisfactory for many patients. Our aim is to provide patients with better options as quickly as possible."

Urovant has struck a licensing deal with Merck which will give it access to late-stage overactive bladder treatment vibegron. The condition afflicts about 33 million Americans in some shape or form, according to the Urology Care Foundation.

Ramaswamy is the founder and CEO of Roivant Sciences, which serves as an umbrella company for a variety of his life science outfits (which all end with the "Vant" moniker). He's probably best known outside the biopharma sphere for executing some of the most impressive biotech IPOs in recent memory, including the $315 million public offering for Alzheimer's and neurological disease-centered Axovant and a $218 million IPO for female health firm Myovant. (Skeptics argue that the model is unsustainable and creating massive valuations with little proof of ultimate success.)

Roivant also encompasses two other companies concentrating on skin conditions and rare disease, both of which are still private. Former Medivation CEO David Hung (whose company was snatched up by Pfizer for its prostate cancer drug Xtandi last year) was hired as Axovant's new chief in April.

Ramaswamy's modus operandi involves snatching up potentially promising experimental drugs that other companies (particularly big pharma firms) don't have the resources to take into clinical trials, aren't interested in because they don't match up with a drug portfolio strategy, or have been deemed too low-reward/high-risk, as he explained to Fortune in an interview last month.

So what's next? If the past three years are any indication, even more licensing agreements, experimental drug acquisitions, and high-profile hires.